Skip to main content

Advertisement

Log in

Antiglutamatergic therapy in Alzheimer's disease – effects of lamotrigine

  • Short Communication
  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

Summary.

It has been proposed that excitotoxic damage by glutamatergic hyperactivity is responsible for neurodegeneration in Alzheimer's disease. Lamotrigine (LTG) inhibits presynaptic glutamate release and is considered to be effective in treatment of other neurodegenerative disorders by its cerebroprotective properties. We used LTG in 11 patients with the diagnosis of probable Alzheimer's disease. 300 mg/day administration of LTG improved word recognition, naming and depressed mood on Alzheimer Disease Assessment Scale (ADAS).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Accepted January 20, 1998; received January 27, 1997

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tekin, S., Aykut-Bingöl, C., Tanrıdağ, T. et al. Antiglutamatergic therapy in Alzheimer's disease – effects of lamotrigine. J Neural Transm 105, 295–303 (1998). https://doi.org/10.1007/s007020050059

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s007020050059

Navigation